New startup ideas · Health and bio · Healthcare and bio

startup idea

Astrid

Monthly at-home blood cartridge that learns your baseline, not the population's.

Astrid ships a reusable reader and a monthly single-use microsampling cartridge that runs a panel of metabolic, inflammatory and hormonal markers from a few drops of blood at home, then charges a consumer subscription for the software that tracks how far each result has drifted from that person's own history and from matched members of the same age, sex and physiology.

Software subscription
Consumer
$100B+ market
Creates a new category
Global from day one

3/5

venture judge

similar startups, last 2 years (3 all-time)

97%

of 4 nearest real companies still alive

yes

8 matching federal grants and programs

Direction supported by government programs and grants

Test it before you build it

$2,400 · 6 weeks · 30 prospects

Prove that 25 longevity self-quantifiers will prepay a $100 refundable reservation and 10 of them will pay $99 per month for a concierge baseline-tracking service run on existing at-home kits, for under $2,400 in 6 weeks

1Focus group: who and where

A longevity self-quantifier aged 30-55 who already pays out of pocket for quarterly blood panels from Function Health, InsideTracker or Marek Health, tracks results in a spreadsheet, and is annoyed that each report compares them to population reference ranges instead of their own last four draws

where to find 30 · r/Biohackers and r/longevity on Reddit (search posts mentioning Function Health or InsideTracker and DM the authors), the Quantified Self forum at forum.quantifiedself.com, and replies to blood-testing threads under Peter Attia and Bryan Johnson content on X; 30 reachable in a week

2Sell first, build later

Founding member slot: a monthly at-home blood draw and a personal-baseline drift report within 48 hours of each sample, starting within 30 days of payment, first 3 months delivered by the concierge service while the cartridge is in development, reader shipped when hardware is ready

the ask · $99 per month for the concierge phase; $100 refundable reservation for the hardware cohort; target long-run price $15 per month software plus consumables at cost

a real yes · A real yes is a completed $100 Stripe reservation or a charged first month of $99. Waitlist emails, upvotes, 'I would definitely buy this' comments and free-trial requests count for nothing

3Small experiments

The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.

1. Baseline-drift teardown calls
$100 · 10 days
Ask 15 prospects to bring their last 3-4 blood panel PDFs to a 30-minute call. Build their personal drift chart live in a spreadsheet, show which markers moved outside their own historical band, and ask what they currently pay per year for testing. One founder runs all calls in week 1-2.
keep going if · 10 of 15 say their current provider does not show this view and 8 of 15 say they would switch for it at equal or lower annual cost
2. Reservation landing page
$700 · 14 days
One page: monthly at-home cartridge plus reader, $15 per month software with a personal baseline, launch cohort capped at 200, $100 refundable reservation via a Stripe Payment Link. Drive traffic with the DM list from the calls plus $500 of Reddit ads targeted at r/Biohackers; no ad claims about diagnosing disease, wellness framing only.
keep going if · 25 reservations from 1,000 unique visitors (2.5 percent), at least 10 from cold traffic rather than the call list
3. Concierge baseline subscription
$600 · 30 days
Sell a 3-month manual version to call participants: each month they take an existing CLIA-lab at-home collection kit the team buys retail (about $95 per kit from an existing consumer lab), and the founder returns a hand-built drift report against their prior draws within 48 hours. Thin Notion dashboard, no code, kit cost passed through at cost plus the $99 per month fee.
keep going if · 10 of 15 call participants pay the first $99 month up front; 7 of 10 pay month 2

4Collect a deposit up front

Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.

$100

per prospect, refundable

how · A $100 refundable reservation collected through a Stripe Payment Link on the landing page, plus the concierge subscription charged monthly through Stripe Checkout set up: Stripe Payment Links ↗

what it reserves · A numbered slot in the 200-person launch cohort, the $15 per month software price locked for life, and priority reader shipment

refund · Refundable in full any time before the reader ships, one click by email, processed within 5 business days

target · 25 reservations plus 10 paying concierge subscribers within 42 days

Go: build it if

25 or more $100 reservations, 10 or more paying concierge members, and month-2 concierge retention of 70 percent or better: the recurring-measurement demand is real before any assay work

Kill: stop if

Fewer than 10 reservations after 1,000 visitors, or fewer than 5 of 15 warm prospects paying $99, or month-2 retention under 50 percent: the buyer wants the novelty panel, not the subscription, which is the Layers failure mode

Would you run this test?

One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.

Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.

Scorecard

One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.

Idea Score, 0-100 · raw 40.6 x 1.64

Open

competition: more crowded than 6% of ideas · headwind x0.97

+3.0

government priorities, secondary (21 matching grants)

Trend

Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.

Entrants 2025-26 vs 2023-24 (similar companies)23
Rounds announced 2025+ in the sector68
Sector direction (live batch)100
2026 trend analyst0

Demand

Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.

YC asks for it (current RFS: idea / sector)30
Someone already pays (similar companies, recent / all-time)25
Operator judge: real pain0

100x potential

Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.

Venture judge50
Market size axis100
Moat axis100
Neighbours still alive1
Technologist judge100

Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were monthly, at-home, blood, cartridge, learns, baseline, not, population.

The idea in full

What: Astrid ships a reusable reader and a monthly single-use microsampling cartridge that runs a panel of metabolic, inflammatory and hormonal markers from a few drops of blood at home, then charges a consumer subscription for the software that tracks how far each result has drifted from that person's own history and from matched members of the same age, sex and physiology. Hardware and consumables are priced at cost so the recurring software fee is the business. Getting there means three years of assay development, manufacturing scale-up and regulatory work before the first paid subscription.
Why now: Strand AI (yc W26) is building multimodal foundation models to predict uncollected patient biology and Carevision Inc. (500global) sells 60-second cardiometabolic screening, both of which need repeated real measurement to be worth anything; the graveyard entry Layers (2025), a 30-minute appointment to measure everything in your body, shows the one-shot clinic version does not survive.
Wedge: first customer and entry point: The existing longevity self-quantifier who already pays for quarterly private blood panels: one cartridge, one panel, sold direct at a lower annual price than two clinic draws.
Path to 100x: Consumer health and longevity spending is well past $100B globally and none of it is a recurring measurement subscription with a personal baseline. The network effect is real on the consumption side: every additional member sharpens the matched-cohort comparison that makes an individual result interpretable, so a member switching to a competitor loses their peer set as well as their history, and families join together because inherited baselines compare.
Ceiling: If regulators require each interpreted marker to clear diagnostic claims, Astrid narrows to a wellness gadget with high churn after the novelty year.
Closest real companies, as the generator saw them: Illume Labs is a 24/7 longevity companion built on data the user does not collect, and Gutgutgoose personalises one intervention; Astrid owns the measurement stream itself, which is the input both of them lack. Layers proved the clinic-visit version dies.
Main risk: At-home microsampling cannot hold clinical-grade precision on enough markers, and drift detection drowns in assay noise.

Five judges

Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).

Venture investor
3/5
Real cohort network effect and $100B+ consumer spend, but three years of assay and manufacturing work before a single paid subscription.
Bootstrapper
1/5
Three years of assay development and manufacturing scale-up before one subscription, on consumer buyers who churn after the novelty year.
Operator
1/5
A consumer longevity subscription priced against quarterly private panels is a vitamin with three years of assay work before the first euro.
Technologist
5/5
Reusable reader plus single-use microsampling cartridge holding clinical precision on metabolic and hormonal markers is three years of assay and manufacturing depth.
Risk
2/5
Three years of assay and manufacturing spend before a euro of subscription, with diagnostic claim rules able to reduce it to a wellness gadget.
trends
1/5
Why-now is one W26 company and a dead clinic startup; at-home blood panels plus three years of assay R&D had no 2025-2026 unlock.

Similar startups in the directory

Companies whose pitch matches most of the idea's terms (monthly, at-home, blood, cartridge, learns, baseline, not, population): 3 all-time, 0 from the last two years. Same matching as Idea Check.

Alltruistsyc W21 · 2021 · Consumersite down
Kid-friendly, at-home volunteer projects in a box, delivered bimonthly
Qvinyc W16 · 2016 · Healthcare and bioalive
Empowering women. Period.
Stata DXplugandplay · Healthcare and bioalive
Stata DX is a developer of a disease management eRapid technology designed to implement custom biomarker panels for clinical studies.

Run this as an Idea Check →

The generator's reference companies

Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.

Public money in this direction

US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.

grants and programs matching the idea

1127

startup-relevant grants in Healthcare and bio

$590M

awarded in the sector, tracked

130

opportunities open now in the sector

Flourish All: Women's Integrated Stress Reduction for Alzheimer's Risk Prevention Using Digital Tools and Biomarker Monitoringawardhigh relevance
NIH / NIA · SBIR phase II · $474K · posted 2025-09-20
Novel Myofunctional Nipple to Prevent Obstructive Sleep Apnea in Infantsawardhigh relevance
NIH / NHLBI · SBIR phase I · $317K · posted 2025-09-15
I-Corps: Translation Potential of a Skin-Tone-Aware Pulse Oximeterawardhigh relevance
National Science Foundation · I-Corps · $50K · posted 2026-08-10
InVitreON: A compact and integrated platform for long-term neuronal culture incubation, recording and closed-loop stimulationawardhigh relevance
NIH / NIMH · SBIR phase I · $457K · posted 2026-08-01
I-Corps: Translation potential of machine learning algorithms for early postpartum depression detectionawardhigh relevance
National Science Foundation · I-Corps · $50K · posted 2026-07-30
A Fully Integrated Platform for Reproducible and Scalable Single-Cell Sequencing in Clinical Researchawardhigh relevance
NIH / NIGMS · SBIR phase II · $383K · posted 2026-06-15
A novel remote blood separation device for at-home plasma collection for HIV-1 testingawardhigh relevance
NIH / NCHHSTP · SBIR phase II · $995K · posted 2025-09-30
Accurate and actionable prediction of impending labor using deep learning on maternal physiological dataawardhigh relevance
NIH / NICHD · STTR phase I · $313K · posted 2025-09-17

All public money by sector →

Market signal

What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.

Healthcare and bio · 130 → 118 → 216 → 173 → 71 new companies 2022 → 2026 · 92% aliveYC S26: 14 in this cluster, 6% of the batch (was 4% in X26) (F26 is still forming: 21 listed)Since February, of 444 YC companies here: 4 acquired, 5 shut down, 37 rewrote their pitch

Healthcare and bio: companies, trend and grants →

Design attributes

The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.

Buyer: Consumer
Business model: Software subscription
Path to 100x: Creates a new category
Market size: $100B+ market
Capital intensity: Capital-heavy (hardware, bio, infra)
Speed to revenue: R&D first, revenue after 3 years
Technical depth: Real engineering
Go-to-market: Self-serve
Moat: Network effects
Geography: Global from day one
Regulation: Some regulation
Vibe: Hot space